Statin‐associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies
International Journal of Rheumatic Diseases · 2024-09 · 27 (9)
DOI: 10.1111/1756-185x.15337 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 16.09.2024. Verfasst von Meera Shah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Indraprastha Apollo Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscle, Skeletal, Muscular Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Statins are the first line of treatment for both primary and secondary prevention of atherosclerotic cardiovascular disease. Despite the positive effects of statins on cardiovascular events, not all patients can use them at an optimized dose. The reason for this is the skeletal muscle side effects, termed statin‐associated muscle symptoms (SAMS). Despite extensive research, the precise pathophysiology of SAMS remains unclear and multiple mechanisms may contribute to this phenomenon. Various therapeutic options are available for the management of SAMS, ranging from rechallenging with the same or a different statin to utilizing non‐statin therapeutic alternatives in patients intolerant to statins. However, the lack of consensus on the definition of SAMS, the absence of a definitive diagnostic test, and lack of a universally accepted management algorithm pose a great challenge in dealing with this entity. This review aims to explore the various pathophysiological mechanisms involved in SAMS and understand the difference between self‐limited toxic myopathy and immune‐mediated myopathy requiring immunomodulatory therapy. The conundrum of statin withdrawal, tapering, and rechallenge in SAMS will also be explored in detail along with the newer non‐statin therapies that are available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Indraprastha Apollo Hospital, New Delhi, India.
- Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, New York, USA.
- Division of Allergy, Department of Internal Medicine, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India.
- Division of Neuromuscular Medicine, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Meera Shah, Karun Shrestha, Chih-Wei Tseng, Aman Goyal, Teerin Liewluck, Latika Gupta
Zitieren
APA
Shah, M., Shrestha, K., Tseng, C. W., Goyal, A., Liewluck, T., & Gupta, L. (2024). Statin‐associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies. International Journal of Rheumatic Diseases, 27(9). https://doi.org/10.1111/1756-185x.15337
Vancouver
Shah M, Shrestha K, Tseng CW, Goyal A, Liewluck T, Gupta L. Statin‐associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies. International Journal of Rheumatic Diseases. 2024;27(9). doi:10.1111/1756-185x.15337
BibTeX
@article{Shah2024,
author = {Shah, Meera and Shrestha, Karun and Tseng, Chih-Wei and Goyal, Aman and Liewluck, Teerin and Gupta, Latika},
title = {Statin‐associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
volume = {27},
number = {9},
doi = {10.1111/1756-185x.15337}
}
EUVIMED